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MaBACKGROUND The renin-angiotensin-aldosterone system plays a key role in blood pressure (BP) regulation and is the
target of several antihypertensive medications. Renal denervation (RDN) is thought to interrupt the sympathetic-
mediated neurohormonal pathway as part of its mechanism of action to reduce BP.
OBJECTIVES The purpose of this study was to evaluate plasma renin activity (PRA) and aldosterone before and after
RDN and to assess whether these baseline neuroendocrine markers predict response to RDN.
METHODS Analyses were conducted in patients with confirmed absence of antihypertensive medication. Aldosterone
and PRA levels were compared at baseline and 3 months post-procedure for RDN and sham control groups. Patients in
the SPYRAL HTN-OFF MED Pivotal trial were separated into 2 groups, those with baseline PRA $0.65 ng/ml/h (n ¼ 110)
versus <0.65 ng/ml/h (n ¼ 116). Follow-up treatment differences between RDN and sham control groups were adjusted
for baseline values using multivariable linear regression models.
RESULTS Baseline PRA was similar between RDN and control groups (1.0  1.1 ng/ml/h vs. 1.1  1.1 ng/ml/h; p ¼ 0.37).
Change in PRA at 3months from baseline was significantly greater for RDN compared with control subjects (0.2 1.0 ng/
ml/h; p ¼ 0.019 vs. 0.1  0.9 ng/ml/h; p ¼ 0.14), p ¼ 0.001 for RDN versus control subjects, and similar differences were
seen for aldosterone: RDN compared with control subjects (1.2  6.4 ng/dl; p ¼ 0.04 vs. 0.4  5.4 ng/dl; p ¼ 0.40),
p ¼ 0.011. Treatment differences at 3 months in 24-h and office systolic blood pressure (SBP) for RDN versus control
patients were significantly greater for patients with baseline PRA $0.65 ng/ml/h versus <0.65 ng/ml/h, despite similar
baseline BP. Differences in office SBP changes according to baseline PRA were also observed earlier at 2 weeks post-RDN.
CONCLUSIONS Plasma renin activity and aldosterone levels for RDN patients were significantly reduced at
3 months when compared with baseline as well as when compared with sham control. Higher baseline PRA levels
were associated with a significantly greater reduction in office and 24-h SBP. (SPYRAL PIVOTAL - SPYRAL HTN-OFF
MED Study; NCT02439749) (J Am Coll Cardiol 2021;77:2909–19) © 2021 The Authors. Published by Elsevier on
behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).N 0735-1097 https://doi.org/10.1016/j.jacc.2021.04.044
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Prior stroke or transient ischemic a
Mean 24-h SBP, mm Hg
Mean 24-h DBP, mm Hg
Office SBP, mm Hg
Office DBP, mm Hg
Mean 24-h heart rate, beats/min
Office heart rate, beats/min
Values are mean  SD or % (n).
ACS ¼ acute coronary syndrome; BMI¼
PRA ¼ plasma renin activity; RDN ¼ ren
SEE PAGE 2920
ABBR EV I A T I ON S
AND ACRONYMS
BP = blood pressure
DBP = diastolic blood pressure
PRA = plasma renin activity
RAAS = renin-angiotensin-
aldosterone system
RDN = renal denervation
SBP = systolic blood pressure
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2910B lood pressure (BP) reduction afterrenal denervation (RDN) has beendemonstrated in several randomized,
sham-controlled trials (1–3). Given the vari-
ability in BP response following RDN, a prac-
tical, predictable, noninvasive, and
pre-procedural measure to identify optimal
candidates for RDN therapies remains a ma-
jor unmet need (4). The renin-angiotensin-
aldosterone system (RAAS) plays a key rolein BP regulation and is the target of several antihyper-
tensive medications. RDN is thought to interrupt
sympathetic activity and reduce hormones of the
RAAS as part of its mechanism of action to reduce
BP (5). In certain animal models, RDN significantly
reduced plasma renin activity (PRA) and renal tissue
norepinephrine (6,7). However, effects of RDN on
the human RAAS, and in particular on PRA, are
elusive because in previous studies, patients were
prescribed antihypertensive medications, which
affected renin and aldosterone levels and
confounded the results (8–13). The present pre-
specified analysis of the SPYRAL HTN-OFF MED
Pivotal trial (14,15) aimed to: 1) evaluate changes in





(n ¼ 116) p Value
54.0  9.8 50.6  11.1 0.015
60.0 (66) 69.0 (80) 0.17
31.2  6.6 30.1  5.1 0.15
0.010
27.3 (30) 31.9 (37)
27.3 (30) 10.3 (12)
2.7 (3) 6.0 (7)
0.9 (1) 0.9 (1)
41.8 (46) 50.9 (59)
1.8 (2) 0 (0) 0.24
17.3 (19) 17.2 (20) 1.00
5.5 (6) 7.8 (9) 0.60
0.9 (1) 0 (0) 0.49
0.9 (1) 1.7 (2) 1.00
0 (0) 0.9 (1) 1.00
ttack 0 (0) 0.9 (1) 1.00
150.9  7.5 150.5  7.9 0.69
98.3  7.5 99.0  6.9 0.51
162.2  7.4 162.5  7.7 0.76
100.9  6.6 102.2  7.2 0.16
73.2  10.6 76.5  10.7 0.020
71.7  10.2 75.4  10.8 0.009
body mass index; BP ¼ blood pressure; DBP ¼ diastolic blood pressure;
al denervation; SBP ¼ systolic blood pressure.whether baseline PRA predicts response to RDN in hy-
pertensive patients in the absence of antihyperten-
sive medications.METHODS
STUDY DESIGN AND RANDOMIZATION. The data,
analytic methods, and study materials are owned by
the sponsor and will not be made available to other
researchers for purposes of reproducing the results or
replicating the procedure.
SPYRAL HTN-OFF MED Pivotal is a multicenter,
single-blind, randomized, sham-controlled trial con-
ducted at 44 sites in Australia, Canada, Germany,
Greece, Ireland, Japan, the United Kingdom, and the
United States, and has been previously described
(14,15). Adult patients (age 20 to 80 years) with office
systolic blood pressure (SBP) $150 and <180 mm Hg,
office diastolic blood pressure (DBP) $90 mm Hg, and
a mean 24-h ambulatory SBP $140 and <170 mm Hg
were enrolled in the trial. The trial complied with the
Declaration of Helsinki, all local ethics committees
approved the research protocol, and all patients pro-
vided written informed consent.
Full details of the randomization strategy have
been described previously (14,15). Briefly, patients
were randomized 1:1 to RDN or sham procedure. Prior
to randomization, patients were required to be off all
antihypertensive medications. Tandem high-
performance liquid chromatography and mass spec-
troscopy of urine and plasma by an independent
laboratory were used to evaluate and confirm absence
of antihypertensive medication usage (16).
PROCEDURES. Treatment with the Symplicity Spyral
multielectrode catheter (Medtronic, Galway, Ireland)
and the Symplicity G3 (Medtronic, Minneapolis,
Minnesota) generator was performed using a stan-
dardized approach of targeting all accessible renal
arterial vessels, including branch vessels and acces-
sory arteries with a diameter >3 to <8 mm (14,15). The
sham procedure consisted of a renal angiogram only.
Office BP was measured in all patients at 2-week
intervals after randomization, and patients
remained off antihypertensive medications unless
there were safety concerns related to uncontrolled
hypertension. Office BP measurements were obtained
via automatic BP monitor (Omron, Omron Healthcare,
Inc., Lake Forest, Illinois). The same arm and BP cuff
size were used for all office BP measurements, and
the patient was seated comfortably, with legs
uncrossed, back supported, and upper arm bared with
no clothing between the arm and BP cuff. Three
TABLE 2 Laboratory Values at Baseline and Changes at 3 Months Post-Procedure in Patients Without Antihypertensive Medications
Measurement
Baseline 3 Months













Plasma renin activity, ng/ml/h
N 115 111 115 113 105 104
Mean  SD 1.0  1.1 1.1  1.1 0.8  0.9 1.2  1.2 0.2  1.0 0.1  0.9 0.001*
Median (IQR) 0.6 (0.3 to 1.4) 0.7 (0.4 to 1.4) 0.5 (0.2 to 1.0) 0.8 (0.5 to 1.5) 0.1 (0.4 to 0.01) 0.02 (0.2 to 0.3)
p value 0.019† 0.14†
Aldosterone, ng/dl
N 119 118 120 119 115 115
Mean  SD 8.3  6.4 8.1  6.5 7.3  4.6 8.6  5.7 1.2  6.4 0.4  5.4 0.011*
Median (IQR) 7.0 (5.0 to 10.0) 6.0 (3.0 to 11.0) 6.0 (4.0 to 10.0) 8.0 (5.0 to 11.0) 1.0 (3.0 to 2.0) 0.00 (2.0 to 3.0)
p value 0.04† 0.40†
Aldosterone renin ratio
N 113 111 112 113 101 104
Mean  SD 10.9  8.4 9.6  8.1 11.5  9.5 10.0  8.0 0.1  7.8 0.3  6.6 0.92*
Median (IQR) 8.3 (4.2 to 16.0) 7.1 (4.0 to 12.0) 9.2 (4.4 to 16.0) 7.2 (4.0 to 13.8) 0.0 (4.0 to 3.1) 0.3 (2.8 to 2.5)
p value 0.88† 0.60†
Serum creatinine, mg/dl
N 126 122 126 121 126 121
Mean  SD 0.9  0.2 0.9  0.2 0.9  0.2 0.9  0.2 0.01  0.1 0.0  0.1 0.87*
Median (IQR) 0.9 (0.8 to 1.0) 0.9 (0.8 to 1.0) 0.9 (0.8 to 1.0) 0.9 (0.8 to 1.0) 0.0 (0.1 to 0.1) 0.0 (0.1 to 0.1)
p value 0.22† 0.71†
eGFR, ml/min/1.73 m2
N 126 122 126 121 126 121
Mean  SD 85.3  15.6 88.7  16.9 86.0  14.8 89.1  15.6 0.7  10.9 0.2  11.6 0.70*
Median (IQR) 84.7 (74.2 to 93.6) 87.4 (77.6 to 97.9) 86.6 (76.4 to 96.3) 88.1 (77.2 to 100.8) 0.0 (7.1 to 8.9) 0.0 (6.2 to 7.4)
p value 0.45† 0.86†
Potassium, mmol/l
N 126 122 126 121 126 121
Mean  SD 4.3  0.4 4.2  0.4 4.3  0.4 4.2  0.5 0.0  0.4 0.03  0.5 0.98*
Median (IQR) 4.2 (4.0 to 4.5) 4.2 (4.0 to 4.4) 4.3 (4.0 to 4.5) 4.2 (4.0 to 4.4) 0.0 (0.2 to 0.2) 0.0 (0.2 to 0.2)
p value 0.89† 0.53†
Sodium, mmol/l
N 126 122 126 121 126 121









0.0 (1.0 to 1.0) 0.0 (2.0 to 1.0)
p value 0.24† 0.014†
*p values from analysis of covariance regression model adjusting for baseline value. †p values from paired Student’s t-tests.
eGFR ¼ estimated glomerular filtration rate; IQR ¼ interquartile range; RDN ¼ renal denervation.
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2911seated BP measurements were obtained, with at least
1 min between each measurement, to obtain an
average measurement for the visit.
The 24-h BP measurements were obtained using an
ambulatory BP monitor (Mobil-O-Graph, I.E.M GmbH,
Stolberg, Germany). The same BP cuff size was used
for all ambulatory measurements using the patient’s
nondominant arm. The 24-h BP measurements were
considered valid if at least 21 daytime readings and 12
night-time readings were recorded.
Plasma renin activity, aldosterone, and aldoste-
rone renin ratio levels were evaluated at a corelaboratory (ACM Global Laboratories, Rochester, New
York) at baseline and 3 months post-procedure. Pa-
tients abstained from all antihypertensive medica-
tions and were requested to fast prior to testing.
Patients had to be out of bed for at least 2 h, after
resting and quietly sitting for a minimum of 5 min but
preferably 30 min before blood was sampled. The
time of day and patient’s position (standing, sitting,
or lying down) during blood sampling was docu-
mented. The same time of day ( 2 h) and patient’s
position was used for collection of blood samples at
later time points. All other laboratory values were
FIGURE 1 Patient Flow Diagram
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Sham Control
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OSBP (N = 51)
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2 weeks
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Of the 331 patients eligible for randomization in the SPYRAL HTN-OFF MED Pivotal trial, 166 were randomized to renal denervation and 165 to
sham control. Our analysis was restricted to patients free of antihypertensive medications at baseline and 3 months. Patients were then
divided into 2 groups based on baseline plasma renin activity <0.65 or $0.65 ng/ml/h. Numbers of patients with available office and 24-h BP
measurements at 2 weeks and 3 months are also shown. 3M ¼ 3 months; ABPM ¼ ambulatory blood pressure measurements;
AH ¼ antihypertensive; BL ¼ baseline; OSBP ¼ office systolic blood pressure; PRA ¼ plasma renin activity.
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2912measured at local laboratories. As suggested in pre-
vious studies (17,18), patients were graded into low
versus normal PRA using a cut-off of 0.65 ng/ml/h.
STATISTICAL ANALYSIS. The aim of this pre-specified
subgroup analysis of the SPYRAL HTN-OFF MED Pivotal
trial was to compare BP changes in patients with baseline
PRA $0.65 ng/ml/h and <0.65 ng/ml/h (18). Enrollment
was not stratified per baseline PRA. Only patients with no
antihypertensivemedicationsatbaselineor3monthswere
included in the analysis. Multivariable linear regression
models were used to test for a significant interaction be-
tween patients with baseline PRA <0.65 ng/ml/h
versus $0.65 ng/ml/h and the treatment group. Patients
were also divided into 4 groups based on quartiles of
baseline PRA, and treatment differences between the
quartiles were compared using interaction tests for trend.
Baseline continuous variables are summarized as mean 
SD and were compared using Student’s t-tests. Within
each treatment arm, paired Student’s t-tests were used to
compare changes in continuous variables from baseline tofollow-up. Categorical variables were summarized as
counts and percentages and were compared between
groups using chi-square or Fisher exact tests for categor-
ical variables. For continuous measures, follow-up treat-
ment differences between RDN and sham control groups
were determined using analysis of covariance models
adjusting for baseline values. Statistical analyses were
performed using SAS for Windows version 9.4 (SAS
Institute, Cary, North Carolina).
RESULTS
For patients with no antihypertensive medications
measured in urine or plasma at baseline or at
3 months, there were 110 patients with
baseline PRA <0.65 ng/ml/h and 116 patients with
baseline PRA $0.65 ng/ml/h. Patients with baseline
PRA $0.65 ng/ml/h were younger and had higher
baseline HR (Table 1). Importantly, office and ambu-
latory BP values were similar for patients with base-
line PRA <0.65 ng/ml/h versus $0.65 ng/ml/h:






























































Changes in 24-h SBP and DBP at 3 months are compared for RDN and sham control patients with baseline PRA <0.65 and $0.65 ng/ml/h.
Follow-up treatment differences between RDN and sham control groups were determined using analysis of covariance models adjusting for
baseline values. Changes in 24-h SBP and DBP for patients with baseline PRA$0.65 ng/ml/h were significantly greater for RDN compared with
sham control patients (p < 0.001 for both). The interaction p value was significant for 24-h SBP (p ¼ 0.019) suggesting that the effect of
RDN on 24-h SBP reduction differs based on baseline PRA. BP ¼ blood pressure; DBP ¼ diastolic blood pressure; PRA ¼ plasma renin
activity; RDN ¼ renal denervation; SBP ¼ systolic blood pressure.
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2913baseline 24-h SBP was 150.9  7.5 mm Hg versus 150.5
 7.9 mm Hg; p ¼ 0.69, and baseline office SBP was
162.2  7.4 mm Hg versus 162.5  7.7 mm Hg; p ¼ 0.76.
Mean baseline PRA was similar between RDN and
sham control groups (1.0  1.1 ng/ml/h vs. 1.1  1.1 ng/
ml/h; p ¼ 0.37) (Table 2). Change in PRA from baseline
to 3 months was significantly greater for RDN (0.2 
1.0 ng/ml/h; p ¼ 0.019) compared with the sham con-
trol group (0.1  0.9 ng/ml/h; p ¼ 0.14); p ¼ 0.001 for
RDN versus sham control group. Similarly, change in
aldosterone from baseline to 3 months was signifi-
cantly greater for RDN (1.2  6.4 ng/dl; p ¼ 0.04)
comparedwith the sham control group (0.45.4 ng/dl;
p ¼ 0.40); p ¼ 0.011 for RDN versus sham control
group.
Changes in BP at 2 weeks and 3 months were
compared for RDN and sham control group based on
baseline PRA (Figure 1). For 24-h SBP, treatment dif-
ference at 3 months was 0.3 mm Hg (95% confidence
interval [CI]: 3.9 to 3.3 mm Hg); p ¼ 0.88 for
baseline PRA <0.65 ng/ml/h and 6.1 mm Hg
(95% CI: 9.4 to 2.9 mm Hg); p < 0.001 for baseline
PRA $0.65 ng/ml/h (interaction p ¼ 0.019) (Figure 2).For 24-h DBP, treatment difference at 3 months
was 1.2 mm Hg (95% CI: 3.5 to 1.1); p ¼ 0.29 for
baseline PRA <0.65 ng/ml/h and 4.2 mm Hg
(95% CI: 6.3 to 2.1); p < 0.001 for baseline
PRA $0.65 ng/ml/h (interaction p ¼ 0.055) (Figure 2).
Similarly, treatment differences for RDN versus
sham control group at 3 months for office SBP
(Figure 3A) and office DBP (Figure 3B) were greater for
patients with baseline PRA $0.65 ng/ml/h. For office
SBP, treatment difference at 3 months
was 2.6 mm Hg (95% CI: 7.0 to 1.8 mm Hg);
p ¼ 0.24 for baseline PRA <0.65 ng/ml/h
and 9.8 mm Hg (95% CI: 14.7 to 4.9 mm Hg);
p < 0.001 for baseline PRA $0.65 ng/ml/h (interaction
p ¼ 0.038). For office DBP, treatment difference at
3 months was 2.0 mm Hg (95% CI: 4.7 to
0.7 mm Hg); p ¼ 0.15 for baseline PRA <0.65 ng/ml/h
and 7.0 mm Hg (95% CI: 10.1 to 3.9 mm Hg);
p < 0.001 for baseline PRA $0.65 ng/ml/h (interaction
p ¼ 0.017). Treatment differences in office SBP and
DBP at 2 weeks post-procedure were also examined,
and consistently greater BP reduction in the baseline
PRA $0.65 ng/ml/h group was seen.
























































































































Changes in office SBP and DBP at 2 weeks and 3 months are compared for RDN and sham control patients with baseline PRA <0.65 and $0.65 ng/ml/h.
Follow-up treatment differences between RDN and sham control groups were determined using analysis of covariance models adjusting for baseline
values. Changes in office SBP and DBP at 2 weeks and 3 months for patients with baseline PRA $0.65 ng/ml/h were significantly greater for RDN compared
with sham control patients (p < 0.001 for all). Interaction p values were significant for office SBP at 2 weeks (p ¼ 0.045) and 3 months (p ¼ 0.038), as
well as office DBP at 3 months (p ¼ 0.017), suggesting that the effect of RDN on BP reduction differs based on baseline PRA in these cases.
OSBP ¼ office systolic blood pressure; other abbreviations as in Figure 2.
Mahfoud et al. J A C C V O L . 7 7 , N O . 2 3 , 2 0 2 1
Renal Denervation and Plasma Renin Activity/Aldosterone J U N E 1 5 , 2 0 2 1 : 2 9 0 9 – 1 9
2914

















































































































Changes in (A) 24-h and (B) office SBP at 3 months are compared for RDN and sham control patients according to quartiles of baseline PRA. Follow-up treatment
differences between RDN and sham control groups were determined using analysis of covariance models adjusting for baseline values. Changes in 24-h and office SBP
for patients in the 2 largest quartiles of baseline PRA were significantly greater for RDN compared with sham control patients. Changes in 24-h and office SBP for
patients in the 2 smallest quartiles of baseline PRA were similar for RDN compared with sham control. However, interaction p values were not significant. Abbreviations
as in Figures 2 and 3.
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Changes in ambulatory SBP from baseline to 3 months were examined for RDN and sham control patients with baseline PRA<0.65 and$0.65 ng/ml/h. Control patients
with baseline PRA <65 and $0.65 ng/ml/h had similar hourly SBP measurements at baseline and 3 months. Hourly blood pressure plots for RDN patients with baseline
PRA $0.65 ng/ml/h show reduction in hourly SBP measurements at 3 months compared to baseline, but less difference in hourly SBP measurements for RDN patients
with baseline PRA <0.65 ng/ml/h. Abbreviations as in Figure 2.
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2916Quartile analysis of changes in office and 24-h SBP at
3 months showed greater reduction in BP for RDN pa-
tients in the highest 2 quartiles of baseline PRA, although
the trends did not reach statistical significance (trend
p ¼ 0.051 for office SBP and p ¼ 0.053 for 24-h SBP)
(Figure 4). A similar evaluation by tertiles of aldosterone
demonstrated no significant relationship of baseline
aldosterone levels with office or 24-h systolic BP changes
at 3 months (Supplemental Figure 1).
The 3-month changes in 24-h SBP also showed
greater BP reduction for the RDN group with baseline
PRA$0.65 comparedwith baseline PRA<0.65 ng/ml/h
(Figure 5).
DISCUSSION
Themajor findings from this pre-specified analysis are:
1) PRA and aldosterone were significantly reduced in
the RDN group compared with the sham control groupat 3 months; and 2) treatment differences at 3 months
between RDN and sham control groups for office and
24-h SBP were significantly greater for patients with
baseline PRA $0.65 ng/ml/h (Central Illustration). To
our knowledge, this is the first report of significant
reductions in PRA and aldosterone in a randomized
trial comparing RDN with sham control in patients not
treated with concomitant antihypertensive medica-
tion. The data also identified PRA as a potential pre-
dictor of response to RDN when antihypertensive
drugs are not present, although further confirmatory
studies are warranted, and it would likely be one of
several predictive factors. Of interest is that differ-
ences in office SBP reduction for patients with baseline
PRA <0.65 ng/ml/h versus$0.65 ng/ml/h were seen as
early as 2 weeks post-procedure. However, the effect
could have occurred far sooner, but first BP measure-
ments were obtained only 2 weeks post-procedure.
These findings are consistent with drug studies
CENTRAL ILLUSTRATION Impact of Renal Denervation on Plasma Renin Activity, Aldosterone, and
Blood Pressure Reduction at 3 Months
Mahfoud, F. et al. J Am Coll Cardiol. 2021;77(23):2909–19.
Renal denervation (RDN) targets the renal nerves to reduce sympathetic nervous system activity with the goal of lowering blood pressure. Laboratory measurements
at 3 months show significantly greater reductions in plasma renin activity (PRA) and aldosterone in the RDN group compared to sham control. Treatment difference
for change in mean 24-h systolic blood pressure for RDN versus sham control at 3 months was greater for patients with baseline PRA $0.65 ng/ml/h, compared with
those with baseline PRA <0.65 ng/ml/h. SBP ¼ systolic blood pressure; SNS ¼ sympathetic nervous system.
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2917(including beta-blockers and angiotensin-converting
enzyme inhibitors) in which BP reductions were
greater in patients with high or normal renin levels
than in low-renin patients (19,20).
The enzyme renin is secreted by the kidneys in
response to efferent sympathetic stimulation and in-
creases BP primarily by producing arterial vasocon-
striction through angiotensin II activation (21). RDN is
hypothesized to lower BP by interrupting both
afferent and efferent renal nerve signaling (22). Renal
efferent nerve ablation has been associated with
reduced PRA levels in multiple animal models of hy-
pertension (6,7,23–25). The results in humans are
inconsistent with an early human case report in
which catheter-based RDN reduced PRA (9), whereas
several clinical trials have reported no change in PRA
following RDN (10–13). Invariably, these trialsincluded patients with uncontrolled hypertension
prescribed several antihypertensive drugs, many of
them affecting RAAS activity. Consistent with the
reduction in renin levels, a difference in aldosterone
levels between groups at 3 months was found in this
study. The absence of a relationship of aldosterone
levels with BP response following RDN, however,
likely reflects the impact of factors other than PRA on
aldosterone secretion, including potassium and so-
dium levels, volume status, and ACTH.
Recent sham-controlled trials have proven the BP-
lowering efficacy of RDN in patients with uncon-
trolled hypertension (1–3,14). A common feature of all
RDN trials is the variability of the treatment effect
among patients (26). Thus, the identification of pa-
tients with a high likelihood of a relevant BP lowering
by using a practical, predictable, noninvasive, and pre-
PERSPECTIVES
COMPETENCY IN PATIENT CARE AND
PROCEDURAL SKILLS: Plasma renin activity and
aldosterone levels are significantly reduced 3 months
after renal artery sympathetic denervation.
TRANSLATIONAL OUTLOOK: Additional studies
are needed to elucidate the relationship between
renal sympathetic activity and the RAAS in patients
with hypertension.
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The most commonly identified predictor of response
to RDN is high baseline SBP (27–31), which in part also
relates to the statistical phenomenon of regression to
the mean (32). Arterial stiffness measured by invasive
pulse wave velocity has also been proposed (33), as
well as noninvasive surrogates as determined by pulse
wave analysis (34) or total arterial compliance (35), all
of which may be markers of sympathetic activity. In
the present study, baseline PRA $0.65 ng/ml/h was
associatedwith significantly greater BP reduction after
RDN for 24-h SBP, office SBP, and DBP at 3 months in
patients without antihypertensive medications. It is
likely that RDN affects PRA levels as part of its mech-
anism of action; thus, higher baseline PRA levels could
predict a greater BP reduction. Herein, we used a cut-
off of 0.65 ng/ml/h, as used in a comparison of re-
sponders and nonresponders of BP reduction to
angiotensin-converting enzyme inhibitors (18). For
use as a predictor of response, the optimal PRA cut-off
will need to be determined prospectively after pro-
spectively powered studies in patients with and
without antihypertensive medications, and baseline
PRA may be only one of several predictive factors.
STUDY LIMITATIONS. Not all patients were adherent
to the protocol requirement to abstain from all anti-
hypertensive medications, but we restricted the
analysis to patients who were determined
medication-free by plasma and urine drug testing.
Alterations in sodium intake may have influenced the
results. However, sodium intake and urinary sodium
excretion were not systematically assessed in this
randomized, sham-controlled trial, but are unlikely to
be imbalanced between the groups. Furthermore, the
influence of baseline PRA levels on response to RDN
will be more complex to interpret in the presence of
antihypertensive medications in a real-world setting.
Although statistically significant changes were docu-
mented, and the trial design allowed robust compar-
isons between treated and sham-controlled patient
groups, this pre-specified analysis was not powered
to detect differences in BP reduction for different
levels of baseline PRA or aldosterone. No statistical
adjustments were made for multiple comparisons.
CONCLUSIONS
Radio-frequency RDN with the multielectrode Symplicity
Spyral system in patientswith hypertensionwhowere not
taking antihypertensive medications was associated with
decreased PRA and aldosterone levels at 3 months
compared with a blinded sham-controlled group. In addi-
tion,patientswithbaselinePRA$0.65ng/ml/hhadgreater
24-h and office SBP reduction at 3 months compared withpatients with baseline PRA <0.65 ng/ml/h. These differ-
ences emerged by 2 weeks following RDN, indicating that
the procedure affects renal physiology as early as 2 weeks
following treatment.
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